Marché nord-américain du diagnostic du cancer de la vessie – Tendances et prévisions du secteur jusqu’en 2030

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché nord-américain du diagnostic du cancer de la vessie – Tendances et prévisions du secteur jusqu’en 2030

  • Medical Devices
  • Publish Reports
  • May 2023
  • North America
  • 350 Pages
  • Nombre de tableaux : 55
  • Nombre de figures : 39

North America Bladder Cancer Diagnostics Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2030
Diagram Taille du marché (année de référence)
USD 1,591.09 million
Diagram Taille du marché (année de prévision)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché nord-américain du diagnostic du cancer de la vessie, par type de test (cystoscopie, test de laboratoire d'urine, biopsie, test d'imagerie et autres), stades (stade I, stade II, stade III et stade IV), type de cancer (cancer de la vessie à cellules transitionnelles, cancer de la vessie à cellules squameuses et autres types de cancer), utilisateur final (hôpital, centres d'imagerie diagnostique, instituts de recherche sur le cancer, laboratoires de diagnostic indépendants et laboratoires associés), canal de distribution (appel d'offres direct et vente au détail) Tendances et prévisions de l'industrie jusqu'en 2030.

Marché nord-américain du diagnostic du cancer de la vessie

Analyse et taille du marché du diagnostic du cancer de la vessie en Amérique du Nord

Le marché nord-américain du diagnostic du cancer de la vessie est fragmenté par nature, car il se compose de nombreux acteurs nord-américains tels que F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV et Bio-Rad Laboratories, Inc., entre autres. La présence de ces entreprises génère des prix compétitifs pour le diagnostic du cancer de la vessie dans toute la région. En raison de la présence de ces acteurs aux niveaux régional et international, les fournisseurs et les fabricants proposent des produits avec des spécifications et des caractéristiques différentes pour tous les budgets. La prévalence croissante du cancer de la vessie stimule la croissance du marché. En outre, la sensibilisation croissante à la détection précoce du cancer de la vessie devrait stimuler la croissance du marché.

Marché nord-américain du diagnostic du cancer de la vessieMarché nord-américain du diagnostic du cancer de la vessie

Data Bridge Market Research estime que le marché nord-américain du diagnostic du cancer de la vessie devrait atteindre la valeur de 1 591,09 millions USD d'ici 2030, à un TCAC de 9,1 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.

Rapport métrique

Détails

Période de prévision

2023 à 2030

Année de base

2022

Années historiques

2021 (personnalisable de 2015 à 2020)

Unités quantitatives

Chiffre d'affaires en millions USD 

Segments couverts

Type de test (cystoscopie, test de laboratoire d'urine, biopsie, test d'imagerie et autres), stades (stade I, stade II, stade III et stade IV), type de cancer (cancer de la vessie à cellules transitionnelles, cancer de la vessie à cellules squameuses et autres types de cancer), utilisateur final (hôpital, centres d'imagerie diagnostique, instituts de recherche sur le cancer, laboratoires de diagnostic indépendants et laboratoires associés), canal de distribution (appel d'offres direct et vente au détail)

Pays couverts

États-Unis, Canada, Mexique

Acteurs du marché couverts

F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthcare GmbH, BD, Illumina, Inc. Neusoft Corporation, Abbott, General Electric Company, Hologic Inc., QIAGEN, Cepheid, Ambu A/S, Time Medical Holding et MinFound Medical Systems Co., entre autres

Définition du marché

Bladder cancer begins when healthy cells in the bladder lining—most commonly urothelial cells—change and grow out of control, forming a mass called a tumor. Urothelial cells also line the renal pelvis and ureters, and urethra. Cancer that develops in the renal pelvis and ureters is also considered a type of urothelial cancer and is often called upper tract urothelial cancer. In most cases, it is treated in much the same way as bladder cancer which is described in this guide. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Benign bladder tumors are very rare.

North America Bladder Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

Rising Incidence of Bladder Cancer Globally

Most gene mutations related to bladder cancer develop during a person's life rather than having been inherited before birth. Some of these acquired gene mutations result from exposure to cancer-causing chemicals or radiation. For instance, chemicals in tobacco smoke can be absorbed into the blood, filtered by the kidneys, and end up in urine, where they can affect bladder cells. Other chemicals may reach the bladder the same way. However, sometimes, gene changes may just be random events that sometimes happen inside a cell without having an outside cause.

Bladder cancer occurs mainly in older people. About 9 out of 10 people with this cancer are over the age of 55. The average age of people when they are diagnosed is 73. The rising cases of bladder cancer among the population are enhancing the use of bladder cancer diagnostic products and hence driving the growth of the bladder cancer diagnostics market.

Rising Awareness for the Early Diagnosis of Bladder Cancer

Bladder cancer awareness month is nationally recognized in the U.S. during the month of May. It aims at bringing together the bladder tumor community to help raise awareness and shine a light on a patient population that is often overlooked. Although bladder cancer is not as common as breast or lung cancer, the need for new and innovative ways to treat bladder tumor patients has never been more critical. Research suggests that more than 720,000 patients in the U.S. are struggling with bladder cancer.

As the current North America health crisis continues to shift with the impact of COVID-19, the importance of understanding the impacts of patient care, education, and cancer research is becoming more apparent than ever. Looking toward the future, there is still much more groundwork to be done in discovering new and effective drugs for bladder tumor patients, as well as a dire need for continuous education on a multitude of challenges we face when treating bladder cancer. 

Bladder cancer awareness month is a movement that is wholly dedicated to these efforts, and even in the midst of a pandemic, the need to help this patient population is still a top priority. Hence, the rising awareness of the early diagnosis of bladder cancer is driving the market's growth.

OPPORTUNITY

Increase in Diagnostic Procedures for Bladder Cancer

Bladder cancer is among the top ten most common cancers globally, causes considerable morbidity and mortality, and is, therefore, a substantial burden for healthcare systems. Several techniques used to diagnose bladder cancer include ultrasound, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI), and, sometimes, Positron Emission Tomography (PET) scans.

Treatment for bladder cancer with a slow growth rate may involve monitoring. Chemotherapy for malignant is occasionally combined with radiation therapy and stem cell transplant. People prefer the treatment and getting diagnosed more. Also, the increasing cancer rates have been a boosting factor for the increasing diagnostic product approval.

RESTRAINT / CHALLENGE

Side Effects of Bladder Cancer Treatment Drugs & Therapies

Chemotherapy (chemo) uses anti-cancer drugs that are usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach almost all areas of the body. However, many chemo drugs aren't able to enter the bladder and reach tumor cells. Bacillus Calmette-Guerin (BCG) is the most common intravesical immunotherapy for treating early-stage bladder cancer. BCG is a germ that's related to the one that causes Tuberculosis (TB), but it doesn't usually cause serious diseases. When BCG is put into the bladder as a liquid through a catheter, it helps "turn on" the immune system cells there, which then attack the bladder cancer cells.

Chemo drugs can cause side effects. These depend on the type and dose of drugs and how long treatment lasts. Common side effects can include hair loss, mouth sores, loss of appetite, nausea & vomiting, diarrhea, increased chance of infections (from having too few white blood cells), easy bruising or bleeding (from having too few blood platelets), fatigue (from having too few red blood cells, changes in metabolism or other factors). Some chemo drugs can also cause other, less common side effects. For instance, cisplatin and carboplatin can also cause kidney damage and hearing loss. Sometimes, the doses of the drugs may need to be reduced, or treatment may need to be delayed or stopped to prevent the effects from getting worse. Hence, the side effects of bladder cancer treatment drugs & therapies may restrain the growth of the North America bladder cancer diagnostics market.

Post-COVID-19 Impact on the North America Bladder Cancer Diagnostics Market

COVID-19 created a negative impact on the North America bladder cancer diagnostics market. The lockdown restriction led to the emergence of various challenges, such as decreased hospital visits and delays in treatment procedures.

The COVID-19 pandemic has impacted the market to an extent in a negative manner. However, increasing government support and advancements in imaging techniques are expected to provide lucrative opportunities for market growth. Moreover, increasing partnerships, acquisitions, and collaboration among market players are expected to further fuel market growth. Also, the growth has been high since the market opened after COVID-19, and it is expected that there will be considerable growth in the sector. The market players are conducting multiple activities to improve imaging techniques for the early detection of bladder cancer. With this, the companies will bring advancement and innovation to the market.

Recent Developments

  • In May 2020, F. Hoffmann-La Roche Ltd acquired Stratos Genomics officially. With this acquisition, the company will also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation for the company.
  • In January 2023, Thermo Fisher Scientific Inc. announced that it had completed the agreement to acquire The Binding Site Group, a North America leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.

North America Bladder Cancer Diagnostics Market Scope

North America bladder cancer diagnostics market is segmented into five notable segments based test type, stages, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

  • Cystoscopy
  • Urine lab test
  • Biopsy
  • Imaging test
  • Others

Based on test type, the market is segmented into cystoscopy, urine lab test, biopsy, imaging test, and others.

Stages

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Based on stages, the market is segmented into stage I, stage II, stage III, and stage IV.

Cancer Type

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

Based on cancer type, the market is segmented into transitional cell bladder cancer, squamous cell bladder cancer, and other cancer types.

End User

  • Hospital
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Independent Dignostic Laboratories
  • Associated Labs

Based on end user, the market is segmented into hospital, diagnostic imaging centers, cancer research institutes, independent diagnostic laboratories, and associated labs.

Distribution Channel

  • Direct Tender
  • Retail Sales

Based on distribution channel, the market is segmented into direct tender and retail sales.

Marché du diagnostic du cancer de la vessie

Analyse/perspectives régionales du marché du diagnostic du cancer de la vessie en Amérique du Nord

Le marché nord-américain du diagnostic du cancer de la vessie est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de test, stades, type de cancer, utilisateur final et canal de distribution comme référencé ci-dessus.

Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada et le Mexique.

Les États-Unis devraient dominer le marché avec la plus grande part de marché. Cette part est attribuable à la présence d'acteurs clés du marché tels que F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV et Bio-Rad Laboratories, Inc., entre autres. La prévalence croissante du cancer de la vessie et l'amélioration des techniques d'imagerie devraient alimenter la croissance du marché au cours de la période de prévision dans cette région.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché du diagnostic du cancer de la vessie en Amérique du Nord

Le paysage concurrentiel du marché nord-américain du diagnostic du cancer de la vessie fournit des détails sur le concurrent. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.

Français Certains des principaux acteurs du marché opérant sur le marché du diagnostic du cancer de la vessie en Amérique du Nord sont F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips NV, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthcare GmbH, BD, Illumina, Inc. Neusoft Corporation, Abbott, General Electric Company, Hologic Inc., QIAGEN, Cepheid, Ambu A/S, Time Medical Holding et MinFound Medical Systems Co., entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TEST TYPE SEGMENT LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE ANALYSIS

4.2 PORTER'S FIVE FORCES MODEL

5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT

6 REGULATORY FRAMEWORK

6.1 REGULATORY SCENARIO IN THE U.S

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY

7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER

7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY

7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER

7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES

7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS

7.3 OPPORTUNITIES

7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER

7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS

7.3.3 INCREASE IN THE GERIATRIC POPULATION

7.4 CHALLENGES

7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING

7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES

8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 CYSTOSCOPY

8.3 URINE LAB TEST

8.3.1 URINE CYTOLOGY

8.3.2 URINALYSIS

8.3.3 URINE TUMOR MARKER TEST

8.3.4 URINE CULTURE

8.3.5 OTHERS

8.4 BIOPSY

8.5 IMAGING TEST

8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN

8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN

8.5.3 ULTRASOUND

8.5.4 INTRAVENOUS PYELOGRAM (IVP)

8.6 OTHERS

9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES

9.1 OVERVIEW

9.2 STAGE IV

9.3 STAGE III

9.4 STAGE II

9.5 STAGE I

10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 TRANSITIONAL CELL BLADDER CANCER

10.3 SQUAMOUS CELL BLADDER CANCER

10.4 OTHER CANCER TYPES

11 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITAL

11.3 DIAGNOSTIC IMAGING CENTERS

11.4 CANCER RESEARCH INSTITUTES

11.5 INDEPENDENT DIAGNOSTIC LABORATORIES

11.6 ASSOCIATED LABS

12 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

13 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION

13.1 NORTH AMERICA

13.1.1 U.S.

13.1.2 CANADA

13.1.3 MEXICO

14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

15 SWOT ANALYSIS

16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET

16.1 F. HOFFMANN- LA ROCHE LTD

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 MERCK KGAA

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 THERMO FISHER SCIENTIFIC INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 KONINLIJKE PHILIPS N.V.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 BIO-RAD LABORATORIES, INC.

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SNAPSHOT

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 AGILENT TECHNOLOGIES, INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 AMBU A/S

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 BD

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 CANON MEDICAL SYSTEMS CORPORATION

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 CEPHEID

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENTS

16.12 FUJIFILM CORPORATION

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 GENERAL ELECTRIC COMPANY

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENTS

16.14 HOLOGIC INC.

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 ILLUMINA INC

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 MINFOUND MEDICAL SYSTEMS CO.,

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 NEUSOFT CORPORATION

16.17.1 COMPANY SNAPSHOT

16.17.2 COMPANY SNAPSHOT

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 QIAGEN

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

16.19 SIEMENS HEALTHCARE GMBH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 TIME MEDICAL HOLDING.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

Liste des tableaux

TABLE 1 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 NORTH AMERICA CYSTOSCOPY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA BIOPSY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA STAGE IV IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA STAGE III IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA STAGE II IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA STAGE I IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA TRANSITIONAL CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA SQUAMOUS CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA OTHER CANCER TYPES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA HOSPITAL IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA CANCER RESEARCH INSTITUTES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA ASSOCIATED LABS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA DIRECT TENDER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA RETAIL SALES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 35 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 36 U.S. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 37 U.S. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 39 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 40 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 41 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 42 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 43 CANADA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 CANADA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 45 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 46 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 47 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 49 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 50 MEXICO URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 51 MEXICO IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 52 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 53 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 54 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 55 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Liste des figures

FIGURE 1 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 12 CYSTOSCOPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET

FIGURE 14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 15 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2022

FIGURE 19 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 21 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE

FIGURE 22 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 23 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 24 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 25 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 27 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 31 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 35 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 36 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 37 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 38 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 39 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The North America Bladder Cancer Diagnostics Market is projected to grow at a CAGR of 9.1% during the forecast period by 2030.
The future market value of the North America Bladder Cancer Diagnostics Market is expected to reach USD 1,591.09 million by 2030.
The major players in the North America Bladder Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, etc.
The countries covered in the North America Bladder Cancer Diagnostics Market are U.S., Canada, Mexico.